| An economic evaluation was undertaken to estimate costs and survival outcomes with clopidogrel, a novel antiplatelet vs comparator drug treatment in patients with ischemic stroke (IS), myocardial infarction (MI) or peripheral arterial disease (PAD).;From a decision analytic model, the use of clopidogrel (;This comprehensive economic evaluation assists in quantifying the "value" and defining rational prescribing guidelines of a new therapy. |
